- Added 18 Apr 2013
Global Alliance for TB Drug Development (TB Alliance)
The Global Alliance for TB Drug Development (TB Alliance) was established in 2000 as a not-for-profit organization that is leading the search and catalysing global efforts to develop new TB regimens that can bring health, and hope, to millions. TB Alliance is a product development partnership (PDP), working to develop better, faster-acting, and affordable TB drug regimens. We combine the research and development expertise of our staff with the skills and resources of our partners to efficiently leverage the most promising science from around the world and accelerate TB drug development. As a virtual drug developer, TB Alliance manages a portfolio of candidate TB compounds from both public and private sector sources, using a variety of licensing and partnership agreements. This model minimizes costs, including overhead and investments in infrastructure, while optimizing scientific capability to speed new TB drug development. TB Alliance currently manages more than 20 projects in its pipeline, including several programs in late-stage clinical trials. A faster-acting, better TB drug regimen will improve health outcomes, save health systems and patients money, and stop the proliferation of deadlier, drug-resistant TB, potentially saving millions of lives. As new treatments are developed, the TB Alliance hopes to reduce the time to cure TB from the current treatment duration — from six months to two years — to our ultimate goal: a TB treatment that can be administered in less than two weeks, similar to those for many other bacterial infections.
We are looking to work with sites who see high populations of TB patients.
If you are interested in working with the TB alliance in future trials, please register on SiteFinder and we will contact you if a suitable study comes up. Thank you